Drug name - Truseltiq

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9067896 HELSINN HLTHCARE Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
Aug, 2028

(5 years from now)

US8552002 HELSINN HLTHCARE Compounds and compositions as protein kinase inhibitors
Aug, 2029

(6 years from now)

CN101035769A HELSINN HLTHCARE Pyrimidine Carbamide Ramification Used As Kinase Inhibitor
Aug, 2013

(9 years ago)

CN102639510A HELSINN HLTHCARE 3-(2, 6--3, 5-Dimethoxy-Phenyl)--1-{6-[4-(4-Ethyl-Piperazin--1-Yl)-Phenyl Amino]-Pyrimidin--4-Yl}--1-Methyl-Urea And Their Salt Form
Apr, 2016

(6 years ago)

CN103121972A HELSINN HLTHCARE Pyridine Urea Derivatives As Kinase Inhibitor
Jun, 2025

(2 years from now)

CN103121972B HELSINN HLTHCARE Pyrimidine Urea Derivatives As Kinase Inhibitors
Jun, 2025

(2 years from now)

IN261843B HELSINN HLTHCARE Pyrimidine Urea Derivatives As Kinase Inhibitors
Jun, 2025

(2 years from now)

IN200606843P1 HELSINN HLTHCARE Pyrimidine Urea Derivatives As Kinase Inhibitors
Jun, 2025

(2 years from now)

EP2418205B1 HELSINN HLTHCARE Pyrimidine Urea Derivatives As Kinase Inhibitors
Jun, 2025

(2 years from now)

EP2409969B1 HELSINN HLTHCARE Pyrimidine Urea Derivatives As Kinase Inhibitors
Jun, 2025

(2 years from now)

EP2409969A1 HELSINN HLTHCARE Pyrimidine Urea Derivatives As Kinase Inhibitors
Jun, 2025

(2 years from now)

EP1761505B1 HELSINN HLTHCARE Pyrimidine Urea Derivatives As Kinase Inhibitors
Jun, 2025

(2 years from now)

EP1761505A1 HELSINN HLTHCARE Pyrimidine Urea Derivatives As Kinase Inhibitors
Jun, 2025

(2 years from now)

EP2418205A1 HELSINN HLTHCARE Pyrimidine Urea Derivatives As Kinase Inhibitors
Jun, 2025

(2 years from now)

EP2509963B1 HELSINN HLTHCARE Crystalline Forms Of 3-(2,6-Dichloro-3,5-Dimethoxy-Phenyl)-1-{6-[4-(4-Ethyl-Piperazin-1-Yl)-Phenylamino]-Pyrimidin-4-Yl}-1-Methyl-Urea And Salts Thereof.
Dec, 2030

(8 years from now)

EP2509963A1 HELSINN HLTHCARE Crystalline Forms Of 3-(2,6-Dichloro-3,5-Dimethoxy-Phenyl)-1-{6-[4-(4-Ethyl-Piperazin-1-Yl)-Phenylamino]-Pyrimidin-4-Yl}-1-Methyl-Urea And Salts Thereof.
Dec, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10278969 HELSINN HLTHCARE Pharmaceutical dosage forms Dec, 2034

(12 years from now)

US11160804 HELSINN HLTHCARE Pharmaceutical dosage forms Dec, 2034

(12 years from now)

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
100MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.